Pfizer to keep 350 jobs at U.K. center; Patent reform bill clears U.S. House;

@FiercePharma: Abbott pushes back closure date on Canadian plant. News | Follow @FiercePharma

> Pfizer will retain about 350 jobs at the site of its doomed U.K. research center in Sandwich, officials announced. Report

> Patent legislation that aims to clear a years-long backlog of applications and allows the patent office set its own fees was approved by the U.S. House of Representatives. News

> Texas Attorney General Greg Abbott filed a deceptive trade practices action against GlaxoSmithKline, claiming the British drugmaker falsely represented the quality of its Kytril, Bactroban, Paxil and Avandamet drugs. Article

> Mylan Pharmaceuticals is set to launch its version of the AstraZeneca Crohn's disease drug Entocort in the U.S. following a victory in a patent litigation case. Story

> Pfizer's board declared a 20-cent dividend for the third quarter, to be paid September 6 to shareholders as of August 5. Pfizer release

> A side effect of many commonly used drugs, including antihistamines and antidepressants: They appear to increase the risk of reduced brain function and early death in older people, a study showed. Item

Biotech News

@FierceBiotech: BMS, AZ diabetes drug will face scrutiny. Item | Follow @FierceBiotech

@JohnCFierce: At a Rothschild conference in Cap Ferrat. Remark by Claus Baestrap (former Lundbeck CEO): In-licensed programs do better than in-house. Follow @JohnCFierce

> FDA shoots down Pfizer, Pain Therapeutics drug. Story 

> Roche, Evotec partner on oncology biomarkers. Item 

And Finally... Nearly a dozen people in Washington state and Montana who had contact with infected goats have been diagnosed with Q fever, a disease common among livestock but rare in humans. Report

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.